About iTeos Therapeutics
iTeos Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2011, and was acquired by Concentra Biosciences in July 2025. Anti-cancer immunotherapies are developed targeting tumor micro-environment. iTeos Therapeutics has raised $204.31 million across 9 funding rounds from investors including Pfizer, Janus Henderson Investors and RTW Investments. The company has 32 employees. iTeos Therapeutics offers products and services including Belrestotug (EOS-448), EOS-984, and EOS-215. Its focus areas include Life Sciences, Immunotherapy, Small Molecule and Immunosuppressive Pathway Inhibitors. Its legal entity is iTeos Therapeutics Inc. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
iTeos Therapeutics was founded in 2011 and is based in Cambridge, United States. Focus is placed on immuno-oncology within the biotechnology sector, where anti-cancer agents are developed to address immuno-metabolism and immunosuppressive cells in the tumor microenvironment. Operations center on advancing a pipeline that includes an Adenosine A2A receptor antagonist currently in early-phase clinical trials, along with a TIGIT immune checkpoint blocking antibody.
- Headquarters Cambridge, United States
- Employees 32
- Stage Acquired
- SectorsHealthcare
- Website iteostherapeutics.com
- Social LinkedIn X
- Acquired by Concentra Biosciences (Jul 2025)
- Legal Name Iteos Therapeutics Inc
- Annual Revenue$35 M (USD)178as on Dec 31, 2024
- Net Profit-$134.41 M (USD)-19as on Dec 31, 2024
- EBITDA-$159.53 M (USD)-6as on Dec 31, 2024
- Total Equity Funding$204.31M (USD)
in 9 rounds
- Latest Funding Round$125.36M (USD), Series B
Apr 2020
- InvestorsPfizer
& 19 more
- Employee Count32
- Acquired byConcentra Biosciences
(Jul 2025)
Products & Services of iTeos Therapeutics
iTeos Therapeutics offers a comprehensive portfolio of products and services, including Belrestotug (EOS-448), EOS-984, and EOS-215.
Immunotherapy targeting immune checkpoints for cancer treatment.
Drug candidate enhancing anti-tumor immune responses in trials.
Under development for advanced malignancies in clinical studies.
Funding Insights of iTeos Therapeutics
iTeos Therapeutics has successfully raised a total of $204.31M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $125.36 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $204.31M
- Total Rounds 9
- Last Round Series B — $125.36M
- First Round $7.81M
(Dec 2011)
- Investors Count 19
All 9 funding rounds of iTeos Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $125.36M | Series B | – | RA Capital Management, Boxer Capital | |
| Jan 2020 | $16.76M | Grant | – | – | – |
| Jun 2018 | $75M | Series B | – | MPM Capital | |
| May 2016 | $1.13M | Grant | – | – | |
| Dec 2015 | $3.2M | Grant | – | – | – |
| Apr 2015 | Grant | – | – | ||
| Dec 2014 | Series A | – | SRIW | – | |
| May 2012 | $3.96M | Series A | – | Ludwig Institute for Cancer Research, Life Sciences Research Partners | – |
| Dec 2011 | $7.81M | Grant | – | – | – |
20 investors in total: 20 institutional.
Investors in iTeos Therapeutics
iTeos Therapeutics has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Janus Henderson Investors and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Buyouts are pursued by SRIW as a private equity firm. | sriw.be | Liege, Belgium | ||
Capital and talent are provided to biotech companies by Curative Ventures. | curativeventures.com | Dallas, United States | ||
Fund+ is focused on investing in life sciences companies. | 2019 | fundplus.be | Leuven, Belgium | |
| vivesfund.com |
Investor details for iTeos Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of iTeos Therapeutics
38 people are tracked at iTeos Therapeutics (16 in leadership, 12 in board & advisors, 10 in team); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Philippe Brantegem | VP, Human Resources | Leadership |
Sandrine Segura Gozzini | Vp, Global Head Of CMC | Leadership |
Angela James | Vice President, Clinical Development | Leadership |
Michel Detheux | President & CEO | Leadership |
Matt Call | COO | Leadership |
David Feltquate | Chief Medical Officer | Leadership |
Clarisse Truong-Maurin | Director, Lead Clinical Development Scientist | Leadership |
Olivier de Henau | Senior Medical Director | Leadership |
Steven Thys | Vice President Clinical Operations | Leadership |
Benoit Dethy | Director Finance And Accounting | Leadership |
Prakash Bolleddula | Senior Director, Clinical Pharmacology | Leadership |
Gregory Driessens | Sr Director, Medicine Development Lead | Leadership |
Madhu Mawal-Dewan | Senior Director, Global Head Medical Writing | Leadership |
Michele Kelly | Senior Director Clinical Quality | Leadership |
Cédric Daems | Head Of Talent Acquisition & HR Business Partner Pre-clinical (director) | Leadership |
Erica Houthuys | Global Program Head, Eos-984 (director) | Leadership |
Aaron Davis | Director | Board & advisors |
Tony Ho | Director | Board & advisors |
Gordon Freeman | Chairman of the SAB | Board & advisors |
Derek Dirocco | Director | Board & advisors |
18 more people are available in the full profile.
Complete people profiles for iTeos Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of iTeos Therapeutics
5 dated milestones of iTeos Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded iTeos Therapeutics is founded.
- Funding First funding round of $7.8M.
- Funding Latest funding round, Series B, of $125.4M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Concentra Biosciences.
Competitors of iTeos Therapeutics
iTeos Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of iTeos Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as iTeos Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iteos Therapeutics
Complete news archive for iTeos Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iTeos Therapeutics
iTeos Therapeutics was founded in 2011.
iTeos Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
iTeos Therapeutics is a funded company, having raised a total of $204.31M across 9 funding rounds to date. The company's 1st funding round was a Grant of $7.81M, raised on Dec 2011.
iTeos Therapeutics has 32 employees.
Annual revenue of iTeos Therapeutics is $35M as on Dec 31, 2024.
iTeos Therapeutics was founded in 2011 and is based in Cambridge, United States. Focus is placed on immuno-oncology within the biotechnology sector, where anti-cancer agents are developed to address immuno-metabolism and immunosuppressive cells in the tumor microenvironment. Operations center on advancing a pipeline that includes an Adenosine A2A receptor antagonist currently in early-phase clinical trials, along with a TIGIT immune checkpoint blocking antibody.
iTeos Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
iTeos Therapeutics offers Belrestotug (EOS-448), EOS-984, and EOS-215.
iTeos Therapeutics has 20 investors. Key investors include Pfizer, Janus Henderson Investors, RTW Investments, Bpifrance, and RA Capital.
iTeos Therapeutics operates through Iteos Therapeutics Inc.
Yes. iTeos Therapeutics was acquired by Concentra Biosciences in July 2025.